Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT010
MIFTS: 58

Diabetic Neuropathy

Categories: Blood diseases, Eye diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetic Neuropathy

About this section

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 38 12 76 54 37 15
Diabetic Neuropathies 55 73

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Eye diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9743
ICD9CM 35 250.6
MeSH 44 D003929
NCIt 50 C26748
SNOMED-CT 68 866003
KEGG 37 H01459
UMLS 73 C0011882
Sources

Summaries for Diabetic Neuropathy

About this section
NINDS : 54 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and diabetic autonomic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and PEDF Induced Signaling. The drugs Pregabalin and Isosorbide Dinitrate have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and skin, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 76 Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions... more...

Sources

Related Diseases for Diabetic Neuropathy

About this section

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.6 AKR1B1 INS NTF3 VEGFA
2 diabetic autonomic neuropathy 32.3 AKR1B1 EPO INS NGF NTF3
3 microvascular complications of diabetes 5 32.1 ACE AKR1B1 INS VEGFA
4 diabetes mellitus 30.3 ACE AKR1B1 EPO INS LEP SOD2
5 diabetic polyneuropathy 30.1 AKR1B1 NGF NTF3 SOD2 VEGFA
6 sleep apnea 30.0 ACE INS LEP
7 hyperglycemia 29.9 AKR1B1 INS LEP
8 diabetes mellitus, noninsulin-dependent 29.9 ACE AKR1B1 CNR1 INS LEP
9 carpal tunnel syndrome 29.7 INS PMP22 VEGFA
10 lipid metabolism disorder 29.6 ACE INS LEP
11 peripheral nervous system disease 29.5 AKR1B1 INS NGF PMP22 SCN9A TRPV1
12 autonomic neuropathy 29.5 AKR1B1 INS NGF NTRK1 SCN9A
13 ischemia 29.5 ACE EPO SOD2 TRPV1 VEGFA
14 arteries, anomalies of 29.4 ACE INS LEP TRPV1 VEGFA
15 amyotrophic lateral sclerosis 1 29.0 CNR1 CNTF GDNF NGF SOD2
16 microvascular complications of diabetes 3 11.3
17 microvascular complications of diabetes 4 11.3
18 microvascular complications of diabetes 6 11.3
19 microvascular complications of diabetes 7 11.3
20 neuropathy 11.2
21 microvascular complications of diabetes 2 10.9
22 abducens nerve disease 10.9
23 argyll robertson pupil 10.9
24 syncope 10.9
25 hypertensive encephalopathy 10.2 ACE EPO
26 renal artery disease 10.2 ACE EPO
27 severe nonproliferative diabetic retinopathy 10.2 INS VEGFA
28 lesion of sciatic nerve 10.2 NGF TRPV1
29 polyneuropathy 10.2
30 cough variant asthma 10.2 NGF TRPV1
31 lipodystrophy, familial partial, type 1 10.2 INS LEP
32 hypoglycemic coma 10.2 INS NTF3 VEGFA
33 askin's tumor 10.2 NGF NTRK1
34 adenomyosis 10.2 NGF TRPV1 VEGFA
35 end stage renal failure 10.1 ACE EPO LEP
36 sick building syndrome 10.1 LEP TRPV1 VEGFA
37 female reproductive system disease 10.1 PARP1 TRPV1 VEGFA
38 reproductive system disease 10.1 PARP1 TRPV1 VEGFA
39 paroxysmal extreme pain disorder 10.1 SCN9A TRPV1
40 gonadal disease 10.1 INS PARP1 VEGFA
41 prolactin producing pituitary tumor 10.1 NGF NTRK1
42 postherpetic neuralgia 10.1
43 autosomal genetic disease 10.1 INS TRPV1 VEGFA
44 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.1 INS LEP
45 burning mouth syndrome 10.1 NGF SCN9A TRPV1
46 retinal vascular disease 10.1 ACE AKR1B1 INS VEGFA
47 paine syndrome 10.1 NGF SCN9A TRPV1
48 somatoform disorder 10.1 NGF SCN9A TRPV1
49 uremia 10.1 EPO INS LEP
50 complete generalized lipodystrophy 10.1 INS LEP

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy
Sources

Symptoms & Phenotypes for Diabetic Neuropathy

About this section

UMLS symptoms related to Diabetic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Neuropathy:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 ACE AKR1B1 CNR1 CNTF GDNF INS
2 growth/size/body region MP:0005378 10.41 ACE AKR1B1 CNR1 GDNF INS LEP
3 homeostasis/metabolism MP:0005376 10.39 ACE AKR1B1 CNR1 CNTF EPO GLO1
4 mortality/aging MP:0010768 10.31 ACE AKR1B1 CNR1 EPO GDNF INS
5 cellular MP:0005384 10.29 CNR1 CNTF EPO GDNF INS LEP
6 immune system MP:0005387 10.27 ACE CNTF EPO GDNF INS LEP
7 cardiovascular system MP:0005385 10.26 ACE EPO GDNF INS LEP NGF
8 hematopoietic system MP:0005397 10.22 ACE CNTF EPO GDNF INS LEP
9 integument MP:0010771 10.22 CNR1 EPO INS LEP NGF NTRK1
10 nervous system MP:0003631 10.21 CNR1 CNTF GDNF INS LEP NGF
11 muscle MP:0005369 10.14 CNTF EPO GDNF INS LEP NGF
12 adipose tissue MP:0005375 10.05 ACE CNR1 INS LEP SOD2 TRPV1
13 liver/biliary system MP:0005370 10 ACE EPO INS LEP SOD2 TRPV1
14 no phenotypic analysis MP:0003012 9.92 CNR1 CNTF INS NGF NTRK1 PARP1
15 normal MP:0002873 9.86 CNR1 EPO INS NGF NTF3 NTRK1
16 renal/urinary system MP:0005367 9.85 ACE AKR1B1 GDNF INS LEP PARP1
17 reproductive system MP:0005389 9.65 ACE CNR1 GDNF INS LEP NTF3
18 vision/eye MP:0005391 9.32 AKR1B1 INS LEP NGF NTF3 NTRK1
Sources

Drugs & Therapeutics for Diabetic Neuropathy

About this section

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 481)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
2
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3 87-33-2 6883
3
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
4
AT-101 Approved, Investigational Phase 4,Phase 3 90141-22-3, 652-67-5 12597
5
Saxagliptin Approved Phase 4 361442-04-8 11243969
6
Metronidazole Approved Phase 4 443-48-1 4173
7
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
8
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
9
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
10
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
11
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
14
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
15
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
16
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
17 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
19
Nabilone Approved, Investigational Phase 4,Phase 3 51022-71-0 5284592
20
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 13422-55-4
21
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
22
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
23
Alginic acid Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 9005-32-7
24
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 85721-33-1 2764
25
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
26
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
27
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
28
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
29
Tramadol Approved, Investigational Phase 4,Phase 3 27203-92-5 33741
30
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
31
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
32
Amitriptyline Approved Phase 4,Phase 2,Not Applicable 50-48-6 2160
33
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
34
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
35
Acetylcholine Approved Phase 4,Phase 2,Not Applicable 51-84-3 187
36
Indapamide Approved Phase 4 26807-65-8 3702
37
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
38
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
39
Cefoxitin Approved Phase 4 35607-66-0 441199
40
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
41
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
42
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
43
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
44
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
45
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
46
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
47
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
48
Sulbactam Approved Phase 4 68373-14-8
49
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
50
Sultamicillin Approved, Investigational Phase 4 76497-13-7

Interventional clinical trials:

(show top 50) (show all 913)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
3 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
4 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
5 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
6 Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers Unknown status NCT02742233 Phase 4 saxagliptin;placebo
7 A Comparative Efficacy Study of DermaPureâ„¢ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
8 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
9 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
10 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
11 Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
12 A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
13 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
14 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
15 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
16 A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
17 Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT00322621 Phase 4 Duloxetine
18 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
19 Evaluation of Rocker sOles in Diabetis Completed NCT02891928 Phase 4
20 Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesametâ„¢ (nabilone)
21 Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
22 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
23 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
24 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
25 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4 pregabalin
26 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
27 Lovaza® and Microvascular Function in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
28 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
29 Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain Completed NCT01089855 Phase 4 Carbamazepine
30 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
31 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
32 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
33 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
34 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
35 A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
36 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
37 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
38 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
39 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
40 Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
41 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4 Pregabalin
42 The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device Completed NCT01352767 Phase 4
43 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
44 Renal Denervation in Diabetic Nephropathy Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
45 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
46 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
47 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
48 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
49 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
50 Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis Completed NCT02123628 Phase 4 duration of the antibiotic therapy

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)
Sources

Genetic Tests for Diabetic Neuropathy

About this section
Sources

Anatomical Context for Diabetic Neuropathy

About this section

MalaCards organs/tissues related to Diabetic Neuropathy:

41
Testes, Spinal Cord, Skin, Bone, Endothelial, Brain, Kidney
Sources

Publications for Diabetic Neuropathy

About this section

Articles related to Diabetic Neuropathy:

(show top 50) (show all 1212)
# Title Authors Year
1
Cure of human diabetic neuropathy by HPLC validated bark extract of Onosma echioides L. root. ( 29629826 )
2018
2
Diabetic neuropathy and painful diabetic neuropathy: Cinderella complications in South East Asia. ( 29371725 )
2018
3
Single fiber F-waves compared with conventional surface F-waves, and their utility in detecting early diabetic neuropathy. ( 29975798 )
2018
4
Neuroprotective effect of duloxetine in a mouse model of diabetic neuropathy: Role of glia suppressing mechanisms. ( 29763613 )
2018
5
Comparison of peripheral nerve blockade characteristics between non-diabetic patients and patients suffering from diabetic neuropathy: a prospective cohort study. ( 29858510 )
2018
6
Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy. ( 29273519 )
2018
7
Cerebral Biochemical Effect of Pregabalin in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial. ( 29951977 )
2018
8
Feasibility and effectiveness of electrochemical dermal conductance measurement for the screening of diabetic neuropathy in primary care. DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy). Rationale and design. ( 29768354 )
2018
9
Hearing Loss in Type 2 Diabetes in Association with Diabetic Neuropathy. ( 29433858 )
2018
10
Tanshinone IIA Improves Painful Diabetic Neuropathy by Suppressing the Expression and Activity of Voltage-Gated Sodium Channel in Rat Dorsal Root Ganglia. ( 29388177 )
2018
11
Fluoxetine pretreatment enhances neurogenic, angiogenic and immunomodulatory effects of MSCs on experimentally induced diabetic neuropathy. ( 29687216 )
2018
12
Neuropathic pain drives anxiety behavior in mice, results consistent with anxiety levels in diabetic neuropathy patients. ( 29922743 )
2018
13
Transcriptome analysis of dorsal root ganglia's diabetic neuropathy reveals mechanisms involved in pain and regeneration. ( 29750992 )
2018
14
Phloretin either alone or in combination with duloxetine alleviates the STZ-induced diabetic neuropathy in rats. ( 29635891 )
2018
15
The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy. ( 29362940 )
2018
16
Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography. ( 29443416 )
2018
17
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. ( 29966615 )
2018
18
Peripheral Glial Cells in the Development of Diabetic Neuropathy. ( 29770116 )
2018
19
Altered Achilles tendon function during walking in people with diabetic neuropathy: implications for metabolic energy saving. ( 29420151 )
2018
20
Gene therapy with the angiogenic neuropeptide secretoneurin ameliorates experimental diabetic neuropathy. ( 29913555 )
2018
21
Bone marrow-derived mesenchymal stem/stromal cells reverse the sensorial diabetic neuropathy via modulation of spinal neuroinflammatory cascades. ( 29933760 )
2018
22
Pharmacodynamics and Pharmacokinetics of Lidocaine in a Rodent Model of Diabetic Neuropathy. ( 29251644 )
2018
23
The correlation between obstructive sleep apnea and diabetic neuropathy: A meta-analysis. ( 29728306 )
2018
24
Nebivolol, a I^-blocker abrogates streptozotocin-induced behavioral, biochemical, and neurophysiological deficit by attenuating oxidative-nitrosative stress: a possible target for the prevention of diabetic neuropathy. ( 29322226 )
2018
25
Expression of macrophage migration inhibitory factor in footpad skin lesions with diabetic neuropathy. ( 29690804 )
2018
26
[EXPRESS] Auricular vagus nerve stimulation enhances central serotonergic function and inhibits diabetic neuropathy development in Zucker fatty rats. ( 29921169 )
2018
27
Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. ( 29191644 )
2018
28
Diabetic Neuropathy - situational analysis in Pakistan. ( 29371708 )
2018
29
Negative Regulation of TRPA1 by AMPK in Primary Sensory Neurons as a Potential Mechanism of Painful Diabetic Neuropathy. ( 29025860 )
2018
30
Hidden dangers revealed by misdiagnosed diabetic neuropathy: A comparison of simple clinical tests for the screening of vibration perception threshold at primary care level. ( 29029862 )
2018
31
Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway. ( 29094308 )
2018
32
Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. ( 29108839 )
2018
33
A novel curcumin derivative for the treatment of diabetic neuropathy. ( 29122628 )
2018
34
Axonal transport in a peripheral diabetic neuropathy model: sex-dimorphic features. ( 29351809 )
2018
35
Greater corneal nerve loss at the inferior whorl is related to the presence of diabetic neuropathy and painful diabetic neuropathy. ( 29459766 )
2018
36
Lumbar sympathectomy can improve symptoms associated with ischaemia, vasculitis, diabetic neuropathy and hyperhidrosis affecting the lower extremities-a single-centre experience. ( 29516399 )
2018
37
Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. ( 29517942 )
2018
38
Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy. ( 29527628 )
2018
39
Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. ( 29533535 )
2018
40
Reducing CXCR4-mediated nociceptor hyperexcitability reverses painful diabetic neuropathy. ( 29533926 )
2018
41
A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy. ( 29565948 )
2018
42
Herbal Remedies: A Boon for Diabetic Neuropathy. ( 29580105 )
2018
43
Unsteady walking as a symptom in type 2 diabetes mellitus: independent association with depression and sedentary lifestyle and no association with diabetic neuropathy. ( 29590256 )
2018
44
Involvement of Macrophage Inflammatory Protein-1 Family Members in the Development of Diabetic Neuropathy and Their Contribution to Effectiveness of Morphine. ( 29593735 )
2018
45
Sildenafil protective effects on high glucose-induced neurotoxicity in PC12 cells: the role of oxidative stress, apoptosis, and inflammation pathways in an in vitro cellular model for diabetic neuropathy. ( 29623781 )
2018
46
Neuroprotective and antinociceptive effects of rosemary (Rosmarinus officinalis L.) extract in rats with painful diabetic neuropathy. ( 29754274 )
2018
47
Erythropoietin: A potential drug in the management of diabetic neuropathy. ( 30021390 )
2018
48
Keratocyte Density Is Reduced and Related to Corneal Nerve Damage in Diabetic Neuropathy. ( 30025082 )
2018
49
The Natural Rotenoid Deguelin Ameliorates Diabetic Neuropathy by Decreasing Oxidative Stress and Plasma Glucose Levels in Rats via the Nrf2 Signalling Pathway. ( 30045011 )
2018
50
Surgical Peripheral Nerve Decompression for the Treatment of Painful Diabetic Neuropathy of the Foot - a Level 1 Pragmatic Randomized Controlled Trial. ( 30081106 )
2018
Sources

Variations for Diabetic Neuropathy

About this section
Sources

Expression for Diabetic Neuropathy

About this section
Search GEO for disease gene expression data for Diabetic Neuropathy.
Sources

Pathways for Diabetic Neuropathy

About this section

Pathways related to Diabetic Neuropathy according to KEGG:

37
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

Pathways related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 64
Show member pathways
 13.47 CNTF EPO GDNF INS LEP NGF
2
PI3K-Akt signaling pathway 37
Show member pathways
 12.69 EPO INS NGF NTF3 NTRK1 VEGFA
3
MAPK signaling pathway 37 1
12.54 INS NGF NTF3 NTRK1 VEGFA
4
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.39 NGF NTRK1 PARP1 TRPV1 VEGFA
5
Neuroscience 4
12.37 CNR1 NGF NTRK1 SCN9A
6
Ras signaling pathway 37
Show member pathways
 12.27 CNR1 INS NGF NTF3 NTRK1 VEGFA
7
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.72 CNR1 NGF NTF3 NTRK1
8
HIF-1 signaling pathway 37
11.69 EPO INS VEGFA
9
HIF-1-alpha transcription factor network 1
11.45 EPO LEP VEGFA
10
Neurotrophic factor-mediated Trk receptor signaling 1
Show member pathways
 11.39 NGF NTF3 NTRK1
11
Microglia Activation During Neuroinflammation: Steady-State Microglia 65
11.15 NGF NTF3 NTRK1
12
Differentiation Pathway 1
10.94 CNTF EPO INS VEGFA
13
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
10.92 CNTF GDNF NGF NTF3 VEGFA
14
Activation of TRKA receptors 66
Show member pathways
 10.54 NGF NTRK1
Sources

GO Terms for Diabetic Neuropathy

About this section

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 ACE CNTF EPO GDNF INS LEP
2 extracellular space GO:0005615 9.61 ACE AKR1B1 CNTF EPO INS LEP
3 axon GO:0030424 9.1 CNR1 CNTF NGF NTF3 NTRK1 SCN9A

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.95 CNTF GDNF NTF3 NTRK1 VEGFA
2 positive regulation of cell proliferation GO:0008284 9.87 CNTF EPO GDNF INS LEP NTF3
3 positive regulation of cell migration GO:0030335 9.84 INS NTF3 SOD2 VEGFA
4 positive regulation of neuron projection development GO:0010976 9.82 CNR1 EPO NTRK1
5 glucose homeostasis GO:0042593 9.8 CNR1 INS LEP
6 aging GO:0007568 9.8 CNR1 EPO NTRK1 SOD2
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.79 NGF NTF3 NTRK1
8 negative regulation of apoptotic process GO:0043066 9.76 AKR1B1 EPO GDNF GLO1 LEP NGF
9 response to nutrient GO:0007584 9.74 CNR1 EPO LEP
10 memory GO:0007613 9.73 CNR1 NGF NTF3
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 CNTF EPO LEP VEGFA
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 INS LEP NTF3
13 regulation of blood pressure GO:0008217 9.69 ACE LEP SOD2
14 sensory perception of pain GO:0019233 9.67 CNR1 NTRK1 SCN9A TRPV1
15 neurotrophin TRK receptor signaling pathway GO:0048011 9.65 NGF NTRK1
16 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.65 GDNF VEGFA
17 macrophage differentiation GO:0030225 9.64 PARP1 VEGFA
18 positive regulation of insulin receptor signaling pathway GO:0046628 9.63 INS LEP
19 positive regulation of Ras protein signal transduction GO:0046579 9.63 EPO NGF NTRK1
20 sympathetic nervous system development GO:0048485 9.62 GDNF NTRK1
21 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.62 NTRK1 TRPV1
22 induction of positive chemotaxis GO:0050930 9.61 NTF3 VEGFA
23 nerve development GO:0021675 9.6 NGF NTF3
24 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.59 INS SOD2
25 commissural neuron axon guidance GO:0071679 9.58 GDNF VEGFA
26 behavioral response to pain GO:0048266 9.58 SCN9A TRPV1
27 nerve growth factor signaling pathway GO:0038180 9.58 NGF NTF3 NTRK1
28 peripheral nervous system development GO:0007422 9.56 GDNF NGF NTF3 PMP22
29 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.48 ACE VEGFA
30 negative regulation of neuron apoptotic process GO:0043524 9.43 CNTF GDNF NGF NTF3 NTRK1 SOD2
31 regulation of signaling receptor activity GO:0010469 9.23 CNTF EPO GDNF INS LEP NGF

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 EPO INS LEP
2 growth factor activity GO:0008083 9.02 CNTF GDNF NGF NTF3 VEGFA
Sources

Sources for Diabetic Neuropathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
14